Puma Biotechnology Inc (PBYI) Social Stream
PUMA BIOTECHNOLOGY INC (PBYI) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering PUMA BIOTECHNOLOGY INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-04 | 6 | $15 | $5 | $8.6 | $4.49 | 91.54% |
| 2022-03-07 | 6 | $15 | $5 | $8.4 | $4.49 | 87.08% |
| 2022-05-09 | 6 | $14 | $5 | $8.2 | $4.49 | 82.63% |
| 2022-05-19 | 5 | $12 | $4 | $7.6 | $4.49 | 69.27% |
| 2022-08-05 | 5 | $11 | $4 | $6.8 | $4.49 | 51.45% |
| 2022-08-08 | 5 | $11 | $4 | $7 | $4.49 | 55.9% |
| 2022-09-17 | 4 | $8 | $4 | $5.666 | $4.49 | 26.19% |
| 2023-11-03 | 3 | $8 | $4 | $5.666 | $4.49 | 26.19% |
| 2023-11-06 | 3 | $8 | $4 | $5.333 | $4.49 | 18.78% |
The Trend in the Analyst Price Target
PBYI's average price target has moved down $1.67 over the prior 15 months.
Over the past 40 weeks, PBYI's average upside potential has been 70.2%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-27 | 3 | 8 | 4 | 5.666 | 4.24 | 33.63% |
| 2023-03-03 | 3 | 8 | 4 | 5.666 | 3.21 | 76.51% |
| 2023-05-08 | 3 | 8 | 4 | 5.666 | 3.20 | 77.06% |
| 2023-06-05 | 3 | 8 | 4 | 5.666 | 3.57 | 58.71% |
| 2023-08-07 | 3 | 8 | 4 | 5.666 | 3.94 | 43.81% |
PBYI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.67 | 1 | 0 | 1 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
PBYI's average broker recommendation rating improved by 0.16 over the prior 24 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for PBYI as an investment opportunity.
- In terms of how PUMA BIOTECHNOLOGY INC fares relative to all US stocks, note that its average analyst price target is higher than 67.78% of that group.
- PBYI has a lower variance in analysts' estimates than -761.92% of stocks in the mid market cap category.
- In the context of stocks in the mid market cap category, PUMA BIOTECHNOLOGY INC's number of analysts covering the stock is greater than 198.52% of them.
- PBYI has a greater upside potential (average analyst target price relative to current price) than 266.21% of Pharmaceutical Products stocks.
Stocks similar to PUMA BIOTECHNOLOGY INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are PCRX, EBS, and SUPN.
View All Top Stocks by Price Target
Is PBYI a Buy, Hold or Sell? See the POWR Ratings now!